
XLRN
Healthcare · Biotechnology · $10.93B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2021
EPS trend, 90 days to now · -3.3% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2021 | After the close | -1.01 | -1.16 | -14.5% |
| Aug 5, 2021 | After the close | -0.85 | -1.05 | -23.6% |
| May 6, 2021 | After the close | -0.84 | -1.05 | -25.1% |
| Feb 25, 2021 | After the close | -0.55 | -0.95 | -71.9% |
| Nov 5, 2020 | After the close | -0.56 | -0.66 | -17.3% |
| Aug 6, 2020 | After the close | -0.58 | -0.34 | +41.4% |
| May 11, 2020 | After the close | -0.88 | -0.95 | -8.1% |
| Feb 27, 2020 | After the close | -0.30 | -0.44 | -44.8% |
| Nov 6, 2019 | After the close | -0.83 | -0.86 | -3.4% |
| Aug 5, 2019 | After the close | -0.40 | -0.34 | +15.4% |
| May 9, 2019 | After the close | -0.57 | -0.74 | -29.4% |
| Feb 27, 2019 | After the close | -0.68 | -0.75 | -10.9% |
| Oct 30, 2018 | After the close | -0.66 |
Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia. The company is also developing Sotatercept, an activin receptor…
| -0.63 |
| +4.1% |
| Aug 2, 2018 | After the close | -0.63 | -0.63 | +0.3% |
| May 8, 2018 | After the close | -0.64 | -0.58 | +10.1% |
| Feb 27, 2018 | After the close | -0.60 | -0.62 | -3.7% |